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Abstract
Objective: Cancer survival has improved in recent years, but data on return to work (RTW)
after cancer are sparsely published. Therefore, this study analysed RTW after cancer.
Methods: Employees diagnosed with breast cancer, genital cancer, gastro-intestinal cancer,
lung cancer, skin cancer, or blood malignancies were selected from an occupational health
register. Sickness absence was followed for 2 years after diagnosis and full RTW at equal
earnings as before sickness absence was assessed for each cancer site using Cox proportional
hazards regression analysis stratifying for age and gender.
Results: 3701 (73%) of 5074 employees with cancer had full RTW after a median duration of
290 days. Employees with lung cancer had the longest duration of sickness absence and only
45% of them had full RTW 2 years after diagnosis compared with 88% of employees with
genital cancer and 87% of employees with skin cancer. Age was associated with the time to full
RTW among employees with genital cancer: women agedX35 years had a longer time to full
RTW compared with womeno35 years and men agedX55 years had a longer time to full RTW
compared with meno35 years. Gender was associated with the time to full RTW among
survivors of blood malignancies with women having a longer time to full RTW than men.
Conclusions: Most employees had full RTW within 2 years after the diagnosis of cancer and
the time to RTW was largely independent of age and gender.
Copyright r 2010 John Wiley & Sons, Ltd.
Keywords: cancer; oncology; epidemiology; sickness absence; occupational rehabilitation
Introduction
Improvements in cancer care, with better prevention
and screening programmes and multidisciplinary
treatment of cancer according to evidence-based
clinical guidelines, have increased cancer survival
in Europe [1]. Cancer survival rates are highest in
Finland, Sweden, Norway and Iceland and lowest
in the Czech Republic, Poland and Slovenia [2].
The estimated proportions of cancer survivors vary
between 21 and 47% in men and 38 and 59% in
women [3]. Given these survival rates, returning
to paid work after cancer is increasingly important,
all the more because social involvement and
income levels improve the quality of life of cancer
survivors [4–6].
Recent studies have reported on employment
rates of cancer survivors using national employ-
ment statistics [7–13]. Overall, cancer survivors
were 1.4 times more likely to be unemployed than
healthy controls [14]. Norwegian cancer survivors
were more frequently unemployed than the cancer-
free population, even when accommodations in
work or lower-wage jobs with reduced earnings
were adjusted for [15]. Danish cancer patients had
a small increased risk of unemployment during 20
years of follow-up, with 12% higher unemploy-
ment among women and 6% among men com-
pared with age-matched referents [16]. The
unemployment rate of Finnish cancer survivors 2
to 3 years after diagnosis was 9% higher than
gender- and age-matched referents [17,18]. How-
ever, employment statistics do not provide insight
in the course of return to work (RTW), which is the
process of occupational rehabilitation after the
diagnosis of cancer.
There has been a steady ﬂow of research on
occupational rehabilitation of cancer survivors in
the eighties and nineties with RTW rates in either
equal earnings or reduced earnings ranging from 30
to 93% 1–8 years after diagnosis [19]. RTW rates
vary remarkably in the literature, despite compar-
able study populations. For example, 88% of
Canadian breast cancer patients returned to work
within 12 months after surgery [20]. In recent
European studies, RTW rates 12 months after
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breast cancer varied between 54 and 63% [21–23].
The diﬀerent RTW rates may be explained by
diﬀerences in the health-care systems and social
insurances across countries [24]. While some
countries emphasise sickness compensation policies
with broad access to disability beneﬁts, other
countries have occupational rehabilitation policies
and restricted access to disability beneﬁts [25]. In
most western European countries, sickness absence
is fully compensated in the ﬁrst year of absence.
The Netherlands have generous sickness absence
compensation policies in which sick-listed employ-
ees are fully compensated in the ﬁrst year of
sickness absence and receive 70% of their income
in the second year of sickness absence, irrespective
of the cause of sickness absence. Thus, not only
work-related injuries are compensated, but also
diseases unrelated to work. Spelten et al. reported
that 36% of Dutch cancer survivors was absent
from work for more than 18 months in 1999
corresponding to 64% RTW in equal or reduced
earnings as before sickness absence [26].
Now that cancer survival has improved, topical
information is needed about sickness absence and
RTW after cancer. There is some recent informa-
tion on RTW after breast cancer [20–23], but data
on RTW with regard to other cancer sites are
sparse. This study presents the course of sickness
absence within 2 years after the diagnosis of cancer
in Dutch employees and assesses the time to full




The sickness absence register of ArboNed Occupa-
tional Health Services (OHS) contains sickness
absence data and medical diagnoses of 1 million
Dutch wage earners working in diﬀerent economic
sectors representative for the Dutch workforce.
Cases were selected from this sickness absence
register if they met the following eligibility criteria:
 Sickness absence due to cancer.
 Aged 18–60 years.
 In permanent paid employment at the time of
diagnosis.
In the Netherlands, sickness absence is medically
certiﬁed by an occupational physician (OP) usually
in the third or fourth week of sickness absence. For
this study, we selected employees who were absent
from work due to medically certiﬁed breast cancer,
genital cancer, gastro-intestinal cancer, lung can-
cer, skin cancer, and blood malignancies (including
lymphomas and leukaemias) diagnosed between 1
January 2004 and 31 December 2006. Approval
from a medical ethics board was not necessary as
we analysed register data on group level and
neither consulted medical ﬁles nor involved the
cancer survivors themselves in the study. Employ-
ees give informed consent to the use of their
sickness absence data for scientiﬁc research at the
time their data are entered in the sickness absence
register.
Methods
Data on sickness absence were gathered from the
OHS register in which the ﬁrst day of sickness
absence is registered as well as the diagnosis on the
sickness absence certiﬁcate issued by the OP and
the dates of RTW. In this study, full RTW, deﬁned
as returning to work at equal earnings as before
sickness absence, was the event of interest, because
RTW in reduced earnings or lower-wage jobs is not
consistently recorded in the OHS register.
Kaplan–Meier curves were computed to illus-
trate the course of sickness absence according to
cancer site in the 2 years after diagnosis. The course
of sickness absence was compared with a reference
curve of 271 834 sickness absences due to non-
malignant causes exceeding 2 months in duration.
The Kaplan–Meier method recalculated the pro-
portion of sickness absence at every event of full
RTW. In the Netherlands, employees are granted
disability pension after 2 years of incapacity to
work. Therefore, sickness absence episodes were
cut oﬀ at 730 days.
The time to full RTW was assessed for each
cancer site by Cox proportional hazards regression
analysis in SPSS for Windows version 14, stratify-
ing for age (o35 years, 35–44 years, 45–54
years,X55 years) and gender (men, women). Cox
regressions yield hazard ratios (HR). A HRo1.0
reﬂects a longer time to full RTW and a HR41.0 a
shorter time to full RTW. Statistical signiﬁcance
was set at the 5% level and concluded for po0.05.
Results
Between January 2004 and December 2006, we
counted 5074 employees who were absent from
work due to cancer; 1806 (36%) of them were men
and 3268 (64%) women. The mean age of these
employees was 47.7 (standard deviation 9.8) years
at diagnosis. Sickness absence due to breast cancer
was most common, followed by female genital
cancer, gastro-intestinal cancer and lung cancer.
3701 employees (73%) had full RTW 2 years after
the diagnosis of cancer and 637 (13%) were
granted disability pension (Table 1). 433 (8%)
employees resigned during sickness absence and
303 (6%) died within 2 years after diagnosis. The
Copyright r 2010 John Wiley & Sons, Ltd. Psycho-Oncology 20: 1001–1006 (2011)
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data of these employees were right censored at the
moment they resigned or died.
The full RTW rates of employees diagnosed with
genital cancer or skin cancer diﬀered from those
with cancer at other body sites. Thirty-three
percent of women with genital cancer were longer
than 6 months absent from work and 17% longer
than 12 months, compared with 46 and 25% of
men with genital cancer. Twenty-nine percent of
employees with skin cancer were longer than 6
months absent from work and 14% longer than 12
months. Figure 1 shows that the course of sickness
absence of employees with genital cancer or skin
cancer was comparable to the course of sickness
absence of employees with non-malignant chronic
disorders (reference).
Sickness absence percentages were higher than
the reference curve for employees with breast
cancer, gastro-intestinal cancer, lung cancer, and
blood malignancies. 74% of women with breast
cancer were absent longer than 6 months and 46%
longer than 12 months. 52% of patients with
gastro-intestinal cancer, 59% of patients with lung
cancer, and 58% of patients with blood malig-
nancies were longer than 12 months absent from
work (Figure 1).
The Cox regression models showed that the time
to full RTW was longer in women with genital
cancer aged 35–44 years (Hazard Rate [HR]50.8
and 95% conﬁdence interval [CI] 0.6–0.9; p5 0.008),
45–54 years (HR5 0.6 and 95% CI 0.5–0.8;
po0.001), and X55 years (HR50.4 and 95% CI
0.3–0.6; po0.001) compared with women with
genital cancer agedo35 years (Table 2). The time
to full RTW in men with genital cancer agedX55
years was longer (HR50.8 and 95% CI 0.6–1.0;
p5 0.037) compared with men aged o35 years.
Full RTW was independent of gender for most
cancer sites, except for blood malignancies. Female
survivors of blood malignancies had a longer
time to full RTW (HR5 0.6 and 95% CI
0.5–0.9; p5 0.005) than male survivors of blood
malignancies.
Discussion
A total of 73% of cancer survivors had full RTW
that is at equal earnings as before sickness absence;
13% were granted disability pension, 8% resigned
their job, and 6% died within 2 years after
diagnosis. Full RTW rates of employees diagnosed
with genital cancer or skin cancer were comparable
to those of employees who were absent from work
due to non-malignant chronic disorders. The rates
of full RTW were considerably lower in patients
diagnosed with breast cancer, gastro-intestinal
cancer, lung cancer, and blood malignancies and
Table 1. Patients (n5 5074) stratified according to cancer site


















Breast 1579 12 1567 47.7 (8.0) 350 (337–363) 1201 (76) 217 (14) 134 (8) 27 (2)
Female genitals 855 — 855 43.9 (9.2) 105 (97–113) 751 (88) 55 (6) 35 (4) 14 (2)
Gastro-intestinal 725 503 222 52.7 (7.5) 385 (354–416) 438 (60) 126 (17) 73 (10) 88 (12)
Lung 448 286 162 53.1 (7.1) 490 (404–576) 204 (45) 65 (15) 88 (20) 91 (20)
Male genitals 406 406 — 47.3 (13.1) 163 (137–189) 355 (88) 25 (6) 18 (4) 8 (2)
Skin 301 181 120 46.4 (9.8) 84 (71–97) 262 (87) 12 (4) 14 (5) 13 (4)
Blood 297 192 105 42.3 (12.5) 456 (387–525) 184 (62) 71 (24) 26 (9) 16 (5)
Other 463 226 237 46.2 (10.8) 320 (280–360) 306 (66) 66 (14) 45 (10) 46 (10)
Total 5074 1806 3268 47.7 (9.8) 290 (279–301) 3701 (73) 637 (13) 433 (8) 303 (6)
aSD5 standard deviation.
bCI5 confidence interval.



























Figure 1. This figure shows the course of sickness absence
following the diagnosis of breast cancer (1579 patients), cancer
of the female (855 patients) and male (406 patients) genitals,
gastro-intestinal cancer (725 patients), lung cancer (448
patients), skin cancer (301 patients), and blood malignancies
(297 patients); the figure also shows a reference curve of
271 834 sickness absences due to non-malignant chronic
disorders
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were in line with cancer survival data in European
adults [27]. Employees with lung cancer were
absent from work for the longest period of time
(median 490 days) and had the worst RTW
prognosis. Women aged X35 years and men aged
X55 years with genital cancer had a longer time to
full RTW compared with survivors of genital
cancer agedo35 years. Women with blood malig-
nancies had a longer time to full RTW than men
with blood malignancies.
Full RTW according to cancer site
Our results show that the duration and course of
sickness absence after cancer depends on the cancer
site. Survivors of genital cancer or skin cancer have
the best RTW prognosis with 88% of employees
having full RTW 2 years after the diagnosis of genital
cancer and 87% 2 years after skin cancer. Testicular
cancer and skin cancer are known to have high
survival rates [28,29]. Our results add that the course
of sickness absence in patients with cancer at these
sites is comparable to that of patients with non-
malignant chronic (i.e. lasting42 months) disorders.
This may be explained by the type of treatment. Skin
cancer, for instance, can often be surgically removed
and genital cancers are treated with surgery, radiation
therapy, and, if appropriate, hormonal therapy.
Furthermore, cervical malignancies are detected early
in the Netherlands, because all women with an age
between 30 and 60 years are called for cervical tissue
screening every 5 years. Therefore, the treatment of
female genital cancer can also be conﬁned to surgery
and radiation therapy in most cases.
Full RTW rates of patients diagnosed with breast
cancer, gastro-intestinal cancer, lung cancer, and
blood malignancies varied between 45 and 76% in
our study population, which is in line with cancer
survival rates in Europe [3,27] and the employment
statistics of Finnish cancer survivors that ranged
from 40 to 74% [17,18]. Patients with these cancers
are often treated intensively with adjuvant che-
motherapy. Chemotherapy usually lasts several
months and is known to postpone RTW [30–32].
Furthermore, chemotherapy has been associated
with long-term eﬀects on higher cognitive function-
ing [33,34], which may delay full RTW in mentally
demanding jobs. Cognitive impairment due to the
neurotoxicity of chemotherapeutics is estimated to
occur in 17–75% of patients and up to 35% may
suﬀer from long-term eﬀects [35]. However, meth-
odological limitations preclude asserting that che-
motherapy is the cause of cognitive impairment [36].
Other factors than chemotherapy may also cause
cognitive dysfunctioning in cancer survivors, for
example fatigue [37], distress [38], and depression
[26,39]. Nieuwenhuijsen et al. found impaired
neuropsychological functioning in one-third of the
cancer survivors, which was related to a lower
vocational functioning [40]. However, the relation-
ship was not statistically signiﬁcant and the authors
concluded that more research is needed to test the
relevance of neuropsychological impairments for
vocational functioning.
Full RTW according to age and gender
Earlier studies have reported opposing results on the
association between the age of cancer survivors and
employment statistics. Some studies found that older
cancer survivors were less likely to be employed than
their referents [7,8,11,26], while Maunsell et al.
reported that 17% of Canadian survivors of breast
cancer aged 50–59 years were employed at the end of
follow-up compared with 10% of their age-matched
referents [41]. Taskila et al. reported that age did not
have modifying eﬀects on employment rates of
Finnish cancer survivors [17]. A recent meta-analysis
conﬁrmed that the age of cancer survivors was not a
prognostic risk factor for future unemployment [14].
We found that age was associated with full RTW
among survivors of genital cancer only, with a
longer time to full RTW in older men and women
compared with those agedo35 years. Age was not
associated with the time to full RTW of employees
with cancer at other body sites.









o35 years 1 1 1 1 1 1 1
35–44 years 1.0 (0.8–1.3) 0.8 (0.6–0.9) 0.9 (0.6–1.2) 0.8 (0.4–1.3) 1a 0.9 (0.6–1.3) 1.0 (0.7–1.5)
45–54 years 1.0 (0.8–1.3) 0.6 (0.5–0.8) 0.8 (0.6–1.2) 0.7 (0.4–1.1) 0.9 (0.6–1.4) 0.9 (0.6–1.4) 0.8 (0.5–1.2)
X55 years 1.3 (1.0–1.6) 0.4 (0.3–0.6) 0.8 (0.6–1.0) 0.8 (0.5–1.3) 1.0 (0.7–1.6) 0.8 (0.6–1.3) 1.0 (0.7–1.5)
Gender
Men — — — 1 1 1 1
Women — — — 1.0 (0.8 – 1.2) 0.8 (0.6–1.1) 0.8 (0.7–1.1) 0.6 (0.5–0.9)
The table shows Hazard Rates (HR) with their 95% confidence intervals between brackets po0.05 and po0.01. A HRo1.0 reflects longer time to full RTW and a
HR41.0 shorter time until full RTW.
aAged 35–44 years were added to the reference group because the group aged o35 years was too small.
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With regard to gender, Short et al. found that
female cancer survivors had higher odds of
unemployment 2–4 years after diagnosis than male
cancer survivors [11]. Our results showed that
gender was only associated with the time to full
RTW after the diagnosis of blood malignancies
with a longer time to full RTW in women
compared with men.
Strengths and limitations of the study
The strength of our study is that it covered a large
population of 1 million Dutch employees, repre-
sentative for the Dutch workforce. Another
strength is the use of medical diagnoses on the
sick-leave certiﬁcates. The validity of these diag-
noses was not tested, but it is unlikely that OPs
write cancer as diagnosis on the sick-leave certiﬁ-
cate of workers who do not have cancer. However,
sick-leave certiﬁcates contain only one diagnostic
code and information on co-morbidity was lacking.
More detailed information on co-morbidity is
probably interesting, because co-morbidity may
hinder RTW [42]. We also had no information
about the sequelae of cancer such as fatigue [37],
distress [38], and depressive symptoms [26,39],
which are often found in cancer survivors [26].
Another limitation of our study is that we had
no access to the medical ﬁles of the patients.
Therefore, information on the extent of cancer
(local, regional, or metastatic) and the type of
treatment was not available. Occupational rehabi-
litation and employment rates have been found to
be associated with cancer type and treatment
modalities [30–32,43,44]. Furthermore, informa-
tion about interventions to facilitate RTW, such
as rehabilitation programmes, work accommoda-
tions (e.g. modiﬁed work tasks, reduction of work
hours), or placement in another job, was not
available in the register data, while such work
accommodations facilitate RTW [19,31].
Finally, we studied full RTW in equal earnings
as before sickness absence. The fact that we
regarded full RTW as the event of interest may
have overestimated the duration of absence from
work. On the other hand, it may have under-
estimated the number of patients who returned to
work, because we assume that more patients will
resume work part-time or in lower-wage jobs.
To conclude, we found that the majority of
cancer survivors had full RTW within 2 years after
diagnosis. Apart from employees with genital
cancer and employees with blood malignancies
RTW did not depend on age and gender.
Practical implications and recommendations
Our results show that full RTW occurs within 3
months in many employees with skin cancer or
genital cancer and in some employees with cancer
at other sites, despite the generous sickness
compensation policies in the Netherlands. This
means that occupational rehabilitation should be
part of the treatment of cancer in an early stage. It
has been reported that RTW is more successful
when improvement of skills or learning new skills
necessary for the employee’s RTW are addressed as
part of the treatment [11]. Physicians can advise
employees with cancer to remain involved in their
work during treatment and support employees
when they resume their work [45]. Occupational
health professionals may advise employers to stay
in contact with the employee to express concern
and compassion. Employers can facilitate RTW of
cancer survivors by creating a supportive ‘welcome
back’ work environment [19,29] and accommodat-
ing work and working conditions [45,46].
Finally, we recommend publishing data on RTW
after cancer from other countries. It would be
interesting to investigate these RTW data in the
context of diﬀerent health-care systems and diﬀer-
ent social insurances.
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